OncoMatch/Clinical Trials/NCT06005818
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
Is NCT06005818 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pembrolizumab for renal cell carcinoma.
Treatment: Pembrolizumab — The goal of this Clinical Study is to understand the outcomes by informing therapy choice for adjuvant treatment in clear cell renal cell carcinoma by using molecular residual disease. The main question\[s\] it aims to answer are: * what is the progression free survival of a cohort of high risk resected RCC patients when treated based on MRD * what is the overall survival of high risk resected RCC patients when treated based on MRD Participants will forgo adjuvant therapy with pembrolizumab if they have no detectable molecular residual disease. Participants will continue on with standard of care pembrolizumab if they do appear to have molecular residual disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage PT2, GR. 4 OR SARCOMATOID, N0, M0, PT3, ANY GR., N0, M0, PT4, ANY GR. N0, M0, PT ANY STAGE, ANY GR., N+, M0 (pathological tumor-node-metastasis and Fuhrman grading)
Intermediate-high risk RCC: pT2, Gr. 4 or sarcomatoid, N0, M0; pT3, Any Gr., N0, M0. High risk RCC: pT4, Any Gr. N0, M0; pT Any stage, Any Gr., N+, M0
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: nephrectomy
Have undergone a partial nephroprotective or radical complete nephrectomy
Cannot have received: systemic therapy for advanced RCC
Exception: unless having recently initiated immunotherapy with pembrolizumab for no more than 6 weeks or 1 dose prior to enrollment
Have received no prior systemic therapy for advanced RCC unless having recently initiated immunotherapy with pembrolizumab for no more than 6 weeks or 1 dose prior to enrollment.
Cannot have received: anticancer therapy
Exception: unless recovered from AEs due to previously administered agents; denosumab may be allowed for bone protective purposes if dosing has been stable for ≥2 weeks before screening
Has received prior anticancer therapy and not recovered from AEs due to previously administered agents. Note: denosumab may be allowed for bone protective purposes if dosing has been stable for ≥2 weeks before screening.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify